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Introduction 
Grover disease (GD) is a transient acantholytic 
dermatosis that most commonly presents in an older 
white male as a highly pruritic rash on the upper 
trunk and proximal extremities with a tendency to 
wax and wane or spontaneously involute. The 
associated rash most commonly appears as 
scattered red-brown or pink papules with variable 
hyperkeratosis and papulovesicles, but the disease 
can also rarely present with eczematous plaques. The 
eruption is usually transient; however, a persistent 
form is also recognized. The average duration of 
symptoms is two-to-four weeks. Known 
precipitating factors include excessive sweating, 
malignancy, high fever, friction, sun exposure, and 
being bedridden. Histopathologic characteristics 
include dyskeratosis and focal acantholysis [1]. The 
histologic features are often compared to Hailey-
Hailey, pemphigus vulgaris, Darier-White disease, 
pemphigus foliaceous, and spongiotic dermatitis. 
Chemotherapeutic drugs are also implicated in the 
development of GD [1]. It is hypothesized that 
chemotherapeutic agents may cause GD through 
excretion in sweat leading to accumulation in the 
epidermis leading to epidermal toxicity [1]. Recent 
reports discuss a higher than expected incidence of 
GD with the administration of BRAF inhibitors, 
including documented case reports of acantholytic 
dermatosis after treatment with vemurafenib [2]. 
Herein, we describe a patient who experienced GD 
following the administration of vemurafenib. 
Abstract 
Grover disease (GD) is an acquired, nonfamilial, 
nonimmune mediated, transient or persistent 
acantholytic dermatosis. Herein, we present a 72-
year-old man who had clinical and histopathologic 
findings of GD following two weeks of treatment with 
vemurafenib without MEK inhibitor. The patient was 
successfully treated with topical emollients and a 
high-potency corticosteroid. Meanwhile, 
vemurafenib was temporarily discontinued. Drug-
induced GD has increasingly been reported in 
patients on BRAF inhibitor monotherapy as an 
immune-related adverse event. The cutaneous side 
effects seem to arise secondary to a paradoxical 
activation of the mitogen-activated protein kinase 
signaling of BRAF inhibitor treatment, leading to 
keratinocyte proliferation. Although the 
pathogenesis of GD has not been delineated, there is 
suggestion of activation of T lymphocytes, 
particularly helper cells under the action of pro-
inflammatory cytokines, resulting in proliferation of 
keratinocytes. Combination therapy with a MEK 
inhibitor appears to prevent BRAF-induced GD.  
Given that there is a higher prevalence of GD in 
patients with hematologic malignancy, a direct 
causal relationship between the initiation of 
vemurafenib therapy and development of GD in this 
case may be difficult to establish. 
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Case Synopsis 
A 72-year-old man presented with a mildly pruritic 
erythematous papular rash involving his arms and 
chest, which is shown in (Figure 1). On physical 
exam, 1-6mm red papules were noted on the 
involved areas, some with central ulceration and 
crusting and an atypical vascular pattern on 
dermoscopy. The skin eruption began two weeks 
prior to presentation after initiation of vemurafenib 
monotherapy for treatment of recurrent hairy cell 
leukemia. The patient was initially diagnosed with 
hairy cell leukemia 14 years previously and he was in 
remission after treatment with cladribine purine 
analog therapy. He denied other symptoms at that 
time. A shave biopsy was performed of a portion of 
the eruption on the right upper quadrant abdomen. 
Pathology results showed prominent suprabasilar 
acantholysis and dyskeratosis with frond-like villi at 
the base and associated lymphocytoplasmacytic 
inflammation (Figure 2). 
Initially, shave biopsy was performed owing to 
concern for eruptive squamous cell carcinoma in the 
setting of vemurafenib use without concurrent MEK 
inhibitor. However, the pathology findings were 
compatible with a Darier-like histologic 
manifestation of GD. Vemurafenib was discontinued 
after consultation with the oncologist and the 
patient was treated with clobetasol 0.05% cream 
twice daily and topical emollients with resolution of 
the rash. Currently, the patient remains off 
vemurafenib therapy and he is in remission from his 
hairy cell leukemia for the past 6 months.  
 
Discussion 
The pathogenesis of GD has not yet been fully 
determined. Risk factors for development of the 
disease include: acute ultraviolet exposure, excessive 
sweating, heat, bed confinement, hematologic 
malignancies, solid tumors, and drugs [3-8]. In fact, 
drug-induced GD has increasingly been reported in 
patients on BRAF-inhibitor monotherapy as an 
immune-related adverse event [6-10]. In one report, 
the authors described two cases in which patients 
developed acantholytic dyskeratosis with 
histological features consistent with a “Grover-like 
rash.” They concluded that BRAF inhibitor-induced 
rash is related to paradoxical activation of the MAP-
kinase pathway resulting in keratinocyte 
proliferation [2]. In a separate study, patients 
enrolled in the phase I/II clinical trial for dabrafenib 
were monitored for the development of new skin 
lesions [11]. Twenty-seven percent of the 
participants developed GD. The authors agree that 
these skin lesions were related to BRAF inhibitor-
induced keratinocyte proliferation. This hypothesis is 
 
Figure 1. Clinical photographs of the patient with red papules 
involving the A) arms, chest, and B) abdomen. 
A 
B 
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supported by the results of a retrospective cohort 
study, which demonstrated that vemurafenib is 
associated with a variety of other hyperkeratotic 
cutaneous adverse reactions including plantar 
hyperkeratosis, verrucal keratosis, squamous cell 
carcinoma, and keratosis pilaris-like reactions [12]. 
The most common cutaneous adverse event 
associated with single agent BRAF inhibitor 
treatment was GD in 42.9% of the cases. In describing 
this finding, the authors agreed with the 
hyperkeratotic mechanism of action described 
above [12]. 
Researchers have postulated several theories in the 
pathogenesis of GD. One theory attributes the 
development of GD to occlusion of damaged eccrine 
ducts. This theory is supported by the association 
with increased seating, heat, and sun exposure [4]. 
However, GD often spares the palms and soles of the 
feet which contain a high density of eccrine glands. 
In drug-induced GD, one proposed mechanism for 
the hyperkeratotic reaction postulates that the 
metabolites generated by the chemotherapeutic 
agents are concentrated by sweat, leading to 
accumulation in the epidermis with resultant 
epidermal toxicity and the subsequent dyskeratosis 
and acantholysis [13]. However, a second theory 
hypothesizes that the transient acantholysis might 
be the result of an off-target effect of the BRAF-
inhibitors [14]. Combination therapy with a MEK 
inhibitor appears to prevent BRAF-induced GD. In a 
retrospective cohort study of melanoma patients, 
Carlos et al. found that no patients treated with 
dabrafenib or vemurafenib combined with 
trametinib developed GD, in comparison to 38.9% of 
patients treated with vemurafenib alone [12]. 
Heidorn et al. propose that selective inhibition of 
BRAF also drives RAS-dependent BRAF binding to 
CRAF, leading to the activation of CRAF and MEK-ERK 
signaling [15]. Therefore, the addition of a MEK 
inhibitor seems to mitigate such effect. 
Owing to the higher occurrence of GD in the patient 
population to which our patient belongs, in addition 
to higher prevalence in those with hematologic 
malignancy, it is difficult to prove direct causal 
relationship between the initiation of vemurafenib 
therapy and development of GD in this case. It is 
important to consider the possibility that this patient 
may have developed GD coincidentally. However, 
onset of the rash shortly after initiation of 
vemurafenib therapy and resolution with 
discontinuation indicates that this is the most likely 
cause. If the patient is restarted on vemurafenib 
therapy in the future with recurrence of GD, this 
would help to support this theory. 
There are previous reports of BRAF therapy induced 
GD in melanoma patients but cases in other types of 
malignancies are not well-documented.  This is 
important because hematologic malignancy, 
specifically hairy cell leukemia, is a known precipitant 
of GD [3, 5]. Therefore, direct causation is difficult to  
 
 
Figure 2. Hematoxylin-eosin stain with A) prominent 
suprabasilar acantholysis and dyskeratosis with frond-like villi at 
the base, 10×, and B) associated lymphocytoplasmacytic 
inflammation, 40×.
A
B
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establish as hematologic malignancy may be a 
further confounding factor in this case. The 
management of the benign skin eruption is based on 
topical corticosteroids and emollients and the 
chemotherapeutic agents should not be 
discontinued but rather temporarily stopped only if 
required. 
 
Conclusion 
Drug-induced Grover disease is increasingly 
prevalent in the setting of BRAF inhibitor  
monotherapy. This immune-related adverse event 
can potentially be prevented with the addition of a 
MEK inhibitor. Patients on BRAF inhibitors require 
routine dermatologic evaluations to prevent or 
recognize cutaneous toxic effects of BRAF inhibitors 
or provide prompt management. 
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